UroGen Pharma (NASDAQ:URGN) Trading 4.5% Higher - Should You Buy?

UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) shares traded up 4.5% during mid-day trading on Wednesday . The company traded as high as $10.91 and last traded at $11.11. 12,087 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 500,716 shares. The stock had previously closed at $10.63.

Wall Street Analysts Forecast Growth

URGN has been the topic of a number of research analyst reports. LADENBURG THALM/SH SH initiated coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price target on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 target price on shares of UroGen Pharma in a research note on Monday, March 10th. Finally, HC Wainwright reduced their price target on shares of UroGen Pharma from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $38.20.

UroGen Pharma Stock Performance

The firm has a 50-day simple moving average of $10.72 and a two-hundred day simple moving average of $11.43. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The company has a market capitalization of $472.46 million, a price-to-earnings ratio of -3.25 and a beta of 0.80.

Remove Ads

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The company had revenue of $24.57 million during the quarter, compared to analysts' expectations of $25.25 million. As a group, sell-side analysts forecast that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Insider Activity at UroGen Pharma

In other news, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the transaction, the insider now owns 145,666 shares of the company's stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the transaction, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On UroGen Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC lifted its stake in shares of UroGen Pharma by 409.3% in the third quarter. Barclays PLC now owns 59,778 shares of the company's stock worth $759,000 after buying an additional 48,040 shares during the last quarter. JPMorgan Chase & Co. lifted its position in UroGen Pharma by 263.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company's stock worth $864,000 after acquiring an additional 49,318 shares during the last quarter. Geode Capital Management LLC boosted its holdings in UroGen Pharma by 8.1% during the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company's stock valued at $5,787,000 after acquiring an additional 34,248 shares during the period. Oppenheimer & Co. Inc. acquired a new stake in shares of UroGen Pharma in the fourth quarter valued at about $126,000. Finally, Bank of New York Mellon Corp grew its position in shares of UroGen Pharma by 7.3% in the fourth quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock valued at $1,001,000 after purchasing an additional 6,430 shares during the last quarter. Institutional investors and hedge funds own 91.29% of the company's stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.